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A B S T R A C T
Background: BK polyomavirus (BKPyV) infection is a common asymptomatic viral infection in the general po-
pulation. Severe complications are seen in immunocompromised individuals, such as polyomavirus-associated
nephropathy (PyVAN) in renal transplant recipients. Information on BKPyV microRNA expressions is scarce,
although polyomavirus-encoded microRNAs have been shown to control viral replication and assist in immune
evasion. Whereas the pathogenic role of rearrangements in JC polyomavirus has been well established, little is
known about BKPyV rearrangements in PyVAN.
Objectives: To assess viral microRNA expression and transcriptional control region (TCR) sequence variation in
PyVAN patients.
Study design: bkv-miR-B1-3p and bkv-miR-B1-5p microRNA expression was quantiﬁed in 55 plasma samples
from 9 PyVAN patients and 2 controls using speciﬁc miRNA assays. TCR architectures among the viral popu-
lations in each patient were characterized by massive parallel sequencing.
Results: bkv-miR-B1-3p and bkv-miR-B1-5p miRNA expression was established in 85.5% and 98.2% of samples,
respectively. On average, an 8.9-fold (bkv-miR-B1-3p) and 8.7-fold (bkv-miR-B1-5p) higher expression levels
were detected in PyVAN patients as compared to controls. Rearranged BKPyV strains with duplications and
deletions were detected in 7/9 PyVAN patients, but 77.6–99.9% of all sequence reads in all samples represented
archetype strains.
Conclusions: The frequent detection and increased expression of miRNAs suggest involvement in PyVAN pa-
thogenesis. Despite the predominance of archetype BKPyV strains, the frequent detection of minor rearranged
viral populations urges further study on their role in severe kidney disease. Our results suggest that miRNA
expression is increased in PyVAN patients, as well as in the presence of rearranged viral strains.
1. Background
Human BK polyomavirus (BKPyV) is a common DNA virus with
overall 80% seroprevalence [1–3]. BKPyV is encountered in early
childhood, after which asymptomatic lifelong persistence is established
in the renourinary tract [4,5]. In immunocompromised individuals,
particularly in renal transplant recipients, reactivation of latent BKPyV
may cause severe complications [4]. Because up to 10% of renal
transplant recipients develop polyomavirus-associated nephropathy
(PyVAN), these patients are screened for BKPyV viremia and viruria
[6]. Presumptive PyVAN diagnosis can be made if high BKPyV load in
plasma or urine (>104 or >107 copies/mL, respectively) for more than
three weeks is observed [6], but histological examination of allograft
biopsy and immunohistochemical SV40 large T antigen staining are
used for deﬁnitive diagnosis [7]. Because no polyomavirus-speciﬁc
treatments are currently available, the treatment of emerging PyVAN is
based on reduction of immunosuppression [8,9].
Asymptomatic primary BKPyV infections are caused by archetype
viral strains, such as the BKPyV strain WW (GenBank accession number
M15987.1), circulating in the population [10,11]. Importantly, the ar-
chetype noncoding control region (NCCR) comprises blocks O (142 bp,
containing viral ori), P (68 bp), Q (39 bp), R (63 bp) and S (63 bp).
Blocks P, Q, R and S constitute the transcriptional control region (TCR)
[12] containing promoters and enhancer elements for early and late
viral genes [13,14]. During BKPyV replication various NCCR re-
arrangements through deletions and duplications may take place
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[15,16]. For the closely related JC polyomavirus (JCPyV) it has been
well established, that NCCR rearrangements are associated with the
development of progressive multifocal leukoencephalopathy (PML)
[17–19]. BKPyV replication is largely dependent on the activity of the
NCCR, which in turn is inﬂuenced by the TCR architecture [14,20–22].
Although rearranged BKPyV strains have been identiﬁed in PyVAN
patients [20,23,24], the association of TCR modiﬁcations in the pa-
thogenesis of BKPyV-associated kidney diseases is not yet clearly un-
derstood. microRNAs (miRNAs) are small noncoding RNA molecules
that control gene expression by binding to mRNAs and by guiding their
degradation [25,26]. Similar to the closely related JCPyV, also BKPyV
encodes two miRNAs, bkv-miR-B1-3p (3p miRNA) and bkv-miR-B1-5p
(5p miRNA), that further regulate viral replication by reducing the
expression of the large T antigen [27,28]. The 3p miRNA, which shares
identical sequence with JCPyV 3p miRNA [29], also assists the virus in
evading the host immune system by reducing recognition of virus-in-
fected cells [30,31]. Studies on the presence and disease association of
JCPyV miRNAs have shown biomarker potential for the JCPyV speciﬁc
jcv-miR-J1-5p in the assessment of PML risk as well as for the devel-
opment of colorectal cancer [32–35]. Previous studies have reported
elevated BKPyV miRNA expression levels in PyVAN patients
[28,36,37], but the role of BKPyV miRNAs in the development of
PyVAN is still not well understood.
2. Objectives
To analyse BKPyV miRNA expression and TCR sequence variation in
plasma of patients with deﬁnitive or presumptive PyVAN, and to assess
whether these viral factors show potential as useful biomarkers in
prognosis and monitoring of renal transplant recipients.
3. Study design
3.1. Patients and samples
The study population was comprised of nine 45–72-year-old
(median age 62.1) renal transplant recipients with high-level BKPyV
viremia (>104 copies/mL) detected by routine screening performed at
3, 6, 9, and 12 months after kidney transplantation. Additional plasma
samples were collected in routine follow-up of viremia after reduction
of immunosuppression at two to four week intervals until viremia was
cleared. Altogether 53 plasma samples (2–12 samples per patient) were
included in the study. TCR architectures were determined from one
sample per patient taken after transplantation. For this, samples with
high viral loads (8500–217000 copies/mL) and producing a strong
amplicon in PCR were selected for sequencing, based on the assumption
that enhanced replication activity may lead to viral sequence variation.
A written informed consent was obtained from all patients. The control
group included two plasma samples from two renal transplant patients
(a 62-year-old female, and a 69-year-old male) with stable graft func-
tion and no evidence of BKPyV viremia or viruria in routine screening
protocol. Viral load of all samples was determined as previously de-
scribed [38].
3.2. miRNA assays
miRNA expression was quantiﬁed using commercially available
TaqMan miRNA assays (Thermo Fisher Scientiﬁc, Waltham, MA, USA)
targeting the bkv-miR-B1-5p (assay ID: 007796_mat), bkv-miR-B1-3p
(006801_mat) and cel-miR-39-3p (000200) miRNAs. The extracted
samples were spiked with Caenorhabditis elegans cel-39-3p miRNA to
control for reverse transcription and miRNA ampliﬁcation. Detailed
description of RNA extractions and miRNA assays are presented in
Supplementary material. If ampliﬁcation was detected in two or three
of the replicates, the sample was interpreted as positive and a mean
threshold cycle (Ct) was calculated. Fold change of miRNA expression
in patients versus controls was calculated according to the 2−ΔΔCt
method [39] by comparing the results of each individual patient to the
mean of both controls.
3.3. Characterization of BKPyV TCR regions
The aim was to sequence complete TCR regions (blocks P, Q, R and
S, as described in [21]) in one continuous read using the MiSeq massive
parallel sequencing platform (Illumina Inc., San Diego, CA). The for-
ward primer was located within the origin of replication (5′- AGA GGC
GGC CTC GGC CTC TTA T −3′, nucleotides 102–123 according to
BKPyV Dunlop strain; GenBank accession number V01108.1), and the
reverse primer at the 5′ end of the agnoprotein gene (5′- AGA AGC TTG
TCG TGA CAG CTG G −3′, nucleotides 399–419), yielding a 319 bp
amplicon. TCR ampliﬁcation and sequence characterization are pre-
sented in detail in Supplementary material. In addition to TCR archi-
tecture, binding sites for AP-1, NFAT, NF-1, Sp1 and p53 transcription




Of the study patients, 7/9 had deﬁnitive biopsy-conﬁrmed
BKPyVAN with positive staining for SV40 large T antigen, whereas 2/9
had presumptive BKPyVAN with negative staining for SV40 at the time
of BKPyV viremia. Two of the biopsy-conﬁrmed patients had graft
dysfunction at the time of established BKPyV viremia. Viremia was
successfully treated and cleared in all patients with reduction of im-
munosuppression. Detailed patient characteristics are presented in
Table 1.
4.2. Quantiﬁcation of miRNAs
Altogether 55 plasma samples were analysed for miRNAs. 5p
miRNA expression was established in 54/55 samples (98.2%) with an
average Ct value of 39.2, and 3p miRNA in 47/55 samples (85.5%) with
an average Ct value of 38.4. Expression of both miRNAs was also es-
tablished in BKPyV DNA negative control patients, with average Ct
values of 41.7 for 5p and 40.0 for 3p. BKPyV miRNA fold changes and
viral loads varied between samples (Table 2). On average, an 8.7-fold
higher expression of 5p miRNA was observed in PyVAN patients as
compared to controls (2.9–19.1-fold in individual patients). The ex-
pression of 3p miRNA was on average 8.9-fold higher among patients as
compared to controls. In 2/9 patients 3p miRNA expression was con-
siderably high (13.6-fold in patient 2, and 51.5-fold in patient 5),
whereas in 7/9 patients the fold changes were more modest at the most
(0.9–5.0). Robust fold changes among biopsy-conﬁrmed PyVAN pa-
tients as compared to presumptive PyVAN patients were also estab-
lished for both miRNAs (mean fold change 2.5 for 5p miRNA and 9.2 for
3p miRNA). A negative correlation was established between viral load
and normalized 5p (−0.61) and 3p (−0.62) miRNA cycle counts
among all samples, indicating a positive correlation between viral load
and the amount of both miRNAs. When correlations were inspected in
each patient individually, a positive correlation was detected for 5p
miRNA in patients 3 (1.0), 7 (0.4) and 8 (1.0), and for 3p miRNA in
patient 8 (1.0), indicating a negative correlation between viral load and
the amount of miRNA.
Of note, the amount of miRNA ampliﬁcation cycles was increased
from 40 cycles recommended by the manufacturer to 45 cycles for
better assessment of late ampliﬁcation. For 5p miRNA, 20/53 patient
samples and 1/2 controls would have remained negative with 40 cycles
of ampliﬁcation. For 3p miRNA, positive signals were detected above
40 cycles in 11/53 patient samples and in 2/2 controls. All results for
BKPyV and cel-39-3p miRNA detection from individual replicate wells
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are presented in Supplementary Table S1.
4.3. TCR sequence characteristics
The majority (77.6% to 97.6%) of all sequence reads in all samples
represented archetype TCR regions (Table 2). From patients 3 and 8
exclusively (99.9%) archetype TCR regions were characterized. Nu-
cleotide numbering is according to the reverse complement of arche-
type BKPyV strain WW TCR sequence (GenBank accession number
M15987.1, nucleotides 182–414). It should also be noted that sequence
read proportions are only indicative and cannot be taken as a direct
measure of viral strains. The archetype strains of patients 4, 5 and 8 had
a 1-bp insertion between nucleotides 400…401, while the archetype
strains of all other patients had identical length with WW TCR. A total
of nine single nucleotide polymorphisms (SNPs, nucleotides 199, 200,
212, 292, 293, 326, 328, 369, 373) were identiﬁed when compared to
the WW strain (Fig. 1), and ﬁve of these (T212C, C326G, G328A,
A369G, T373G) were located in the binding sites for transcription factor
NF-1.
From six biopsy-conﬁrmed BKPyVAN patients and from one
presumptive BKPyVAN patient modiﬁed TCR regions were identiﬁed
(Table 2, Fig. 2). The proportion of modiﬁed TCR sequence reads was
considerable in two BKPyVAN patients (15.9% for patient 6 and 22.4%
for patient 7), but for the other patients the proportion was approxi-
mately 3.0%. Although the modiﬁcations were unique for each patient,
similarities in TCR architectures were observed. From four patients,
TCR regions with P-(Q)-(P)-Q-R-S architecture (brackets indicate a
truncated block) containing duplications of partial P and Q blocks were
identiﬁed. The modiﬁed BKPyV strains of patients 1, 4, 6 and 9 had 98-
bp (P6-68 and Q1-35), 41-bp (P61-68 and Q1-33), 50-bp (P24-68 and
Q1-5) and 82-bp (P23-68 and Q1-36) duplications, respectively. In two
patients a P-(Q)-(R)-S architecture with partial Q and R block deletions
was characterized. Patient 2 had a 58-bp deletion (Q37-39 and R1-55)
and patient 7 a 41-bp (Q26-39 and R1-27) deletion. From patient 5 with
graft dysfunction and biopsy-conﬁrmed BKPyVAN three distinct viral
strains with diﬀerent TCR modiﬁcations were characterized. One viral
strain had a P-(Q)-(P)-Q-R-S architecture with a 52-bp duplication of
partial P (P22-68) and Q (Q1-5) blocks, one strain a P-Q-(R)-S archi-
tecture with partial R block (R1-51) deletion, and one strain a unique P-
Q-(P)-Q-R-S architecture with 86-bp duplication of truncated P (P22-
68) and a complete Q block. The proportions of modiﬁed TCR sequence
reads were 1.2%, 5.9% and 1.2%, respectively. No obvious association
between the TCR sequence variation and clinical characteristics was
established.
Duplications and deletions of archetypal P and Q blocks aﬀected the
number of binding sites of transcription factors AP-1, NFAT, NF-1, Sp1
and p53 (Table 3). In TCR regions with duplications, additional binding
sites were observed, while deletions resulted in loss of binding sites for
NF-1 or Sp1.
5. Discussion
This study assessed BKPyV microRNA expression and sequence
variation of the viral regulatory region in severe BKPyV-associated
disease among renal transplant recipients. Expression of viral 3p and 5p
miRNAs was established in the majority of samples, and sequencing
revealed the presence of both archetype and rearranged strains. The
predominance of archetype TCR sequences observed in this study sug-
gests that archetype rather than rearranged BKPyV strains are asso-
ciated with the development of PyVAN. In this study, TCR regions were
characterized from one sample collected at the peak viral load period,
assuming that due to active viral replication possible rearrangements
may have arisen. To further assess the emergence and impact of re-
arrangements on viral replication, miRNA expression and PyVAN de-
velopment, several samples at diﬀerent time points, and also before the
onset of the disease should be analysed. Minor modiﬁcations such as
single-nucleotide deletions or insertions seem to occur upon BKPyV
reactivation in the kidneys [42], and such “archetype-like strains” are
the most prevalent [10,21]. Archetype-like strains, possessing SNPs and
one-nucleotide insertions as compared to the archetypal WW strain,
were the most prominent also in the present study. All except two of
these (C326G, G328A) had been previously identiﬁed in
Table 1
Clinical patient characteristics.
Patient ID ISa Time of BKPyV
viremia (months)b












1 CsA 3 58600 No MMF cessation, CsA
dose reduction
PyVAN (A) 48 60
2 CsA 3 401000 No MMF cessation, CsA
dose reduction
PyVAN (A) 53 47
3 CsA 12 26700 No No treatment No PyVAN in
biopsy
18 34
4 Tac 6 89100 No MMF cessation PyVAN (B) 91 49
5 CsA 6 256000 Yes MMF cessation, CsA
dose reduction
PyVAN (A) 60 93
6 d CsA 3 11200 No MMF cessation, CsA
dose reduction
PyVAN (A) 45 11
7 e CsA 5 29600 Yes MMF cessation PyVAN (B) 26 60
8 CsA 6 2700 No MMF cessation PyVAN (A) 72 68
9 Tac 12 102800 No MMF dose reduction No PyVAN in
biopsy
14 47
10f Tac – – – – – 50 26
11f CsA – – – – – 26 92
IS= immunosuppressive treatment; CsA=Cyclosporine-based immunosuppression; Tac= tacrolimus-based immunosuppression; MMF=mycophenolate; PyVAN=polyomavirus-as-
sociated nephropathy; eGFR=glomerular ﬁltration rate, calculated with the CKD-EPI equation [52].
a Immunosuppression was a combination of cyclosporine or tacrolimus, mycophenolate, and steroids. Induction therapy was not used in any of these patients.
b Time of BKPyV viremia diagnosis in months after kidney transplantation.
c PyVAN stages and diagnosis of presumptive and deﬁnitive PyVAN were deﬁned as described in [51].
d After reduction of immunosuppression, patient 6 developed chronic antibody-mediated rejection and severe irreversible graft dysfunction and is approaching end-stage kidney failure
45 months after transplantation.
e Patient 7 with a well-functioning kidney died at 26 months after transplantation due to causes unrelated to BKPyV (severe peripheral vascular disease and septic infection after limb
amputation).
f Controls, renal transplant recipients with stable graft function and no evidence of BKPyV viremia or viruria.
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Table 2
Results for miRNA detection and TCR characterization of nine PyVAN patients.
–=Viral load below detection range (<400 copies/mL), or miRNA not detected.
Ctrl= control sample; ND=not done; TCR= transcriptional control region.
aBKPyV miRNA Ct values were normalized by subtracting the mean Ct value of spiked cel-miR-39-3p miRNA from the mean Ct values of each BKPyV miRNA (ΔCt).
bFold change gives the fold diﬀerence in miRNA expression levels in each patient as compared to controls. First, the mean ΔCt of controls was subtracted from the mean ΔCt
of each individual patient to produce ΔΔCt. The fold change was then calculated according to the 2−ΔΔCt method [39].
cTCR sequence analysis of patient 8 was performed on a sample which was not analysed for miRNA detection.
dSample from which the TCR architecture was characterized.
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immunosuppressed patients without BKPyV-related disease [14,21,42].
The two newly identiﬁed mutations were located in the NF-1 binding
site.
In 7/9 patients, modiﬁed TCR sequences were additionally identi-
ﬁed. Similar modiﬁcations have been identiﬁed in the Gardner strain
[43], which is the prototype rearranged strain of BKPyV, as well as in
rearranged strains from renal transplant patients with PyVAN
[20,23,24,44] and from a patient with tubulointerstitial nephritis [45].
Both patients with graft dysfunction had R block deletions, and in pa-
tient 5 with three distinct modiﬁed BKPyV strains, the strain with
partial R block deletion had higher read counts than the other two
modiﬁed strains. These particular deletions might be associated with
more severe kidney problems, but it cannot be established based on
only two patients. Furthermore, all rearranged strains had retained the
archetypal S block containing hormone-response elements that may
enhance productive BKPyV infection [46]. All rearrangements aﬀected
the number of AP-1, NFAT, NF-1, Sp1 or p53 binding sites, suggesting
that these transcription factors may modulate BKPyV replication and
presumably have a role in the development of PyVAN. AP-1, NFAT, NF-
1 and Sp1 have all been shown to regulate the transcription of BKPyV
early and late genes in vitro [40,41,47,48]. Further studies, including
RNASeq or ChIPSeq approaches are needed to analyse the true impact
of rearrangements and modiﬁcations in transcription factor binding
sites on BKPyV gene expression, and to assess the biological relevance
of these alterations.
Similar to a previous study [36], we observed a positive correlation
between viral loads and the amount of miRNAs. Viral miRNAs were also
detected in some BKPyV-DNA-negative samples, which could be due to
the 45 ampliﬁcation cycles allowing the detection of very low miRNA
levels. Virus-encoded miRNAs have proven to be essential in the es-
tablishment of viral persistence and development of polyomavirus-as-
sociated chronic diseases [49,50]. Previous studies have shown that
BKPyV miRNAs limit viral replication through inhibition of large T
antigen (LTAg) expression [27,28]. A study in a natural host cell model
Fig. 1. TCR sequence comparison of archetype BKPyV strains. Archetype TCR regions from nine PyVAN patients (P1-9_arc, ‘P’ indicating patients 1 through 9 and ‘arc’ describing an
archetype-like strain) were aligned with WW archetype BKPyV strain (BKPyV_WW). Dark and light blue colours indicate either purine (A, G) or pyrimidine (C, T) identity, and a dash
indicates a gap. Black arrows indicate the starting position of sequence blocks. Black dots represent ten nucleotide intervals. Nucleotide numbering is according to archetype WW strain. A
multiple sequence alignment tool (Kalign) and a multiple alignment viewer tool (MView) were used. (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
Fig. 2. TCR sequence comparison of modiﬁed BKPyV strains. Modiﬁed TCR regions from seven (P1-9_mod, ‘P’ indicating the patient and ‘mod’ describing a modiﬁed strain) BKPyVAN
patients were aligned with WW archetype BKPyV strain (BKPyV_WW). Dark and light blue colours indicate either purine (A, G) or pyrimidine (C, T) identity, and a dash indicates a gap.
Black arrows indicate the starting position of sequence blocks, which are deﬁned with black lines. Black dots represent ten nucleotide intervals. Nucleotide numbering is according to the
archetype WW strain. A multiple sequence alignment tool (Kalign) and a multiple alignment viewer tool (MView) were used. (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
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showed that high miRNA expression levels speciﬁcally controlled the
replication of archetype BKPyV strains, but not the replication of re-
arranged variants with high LTAg expression levels [27]. In our study,
high viral loads of predominantly archetype BKPyV strains were de-
tected along with high 5p miRNA expression levels, suggesting that
viral replication was not restricted. However, the correlations in in-
dividual patients suggest that viral replication was limited if only ar-
chetype BKPyV strains were present. This raises the question whether
coexistence of rearranged variants, albeit in minority, may enable ef-
ﬁcient virus replication with simultaneous high 5p miRNA expression.
Coexistence of both rearranged and archetype strains in the plasma of
PyVAN patients has been reported in a previous study, where the
emergence of rearrangements was linked to increased viral replication
[20].
For 3p miRNA the expression levels were considerably lower in
most patients. Intriguingly, the patient with three modiﬁed BKPyV
strains had extremely high 3p miRNA expression as compared to con-
trols. By contrast, in patients harbouring solely archetype strains 3p
miRNA expression levels were similar to controls. 3p miRNA has been
shown to reduce the immune recognition of virus-infected cells, thus
enabling viral persistence [30,31]. Although low 3p miRNA expression
levels do not support an essential role in the development of PyVAN, we
show here that elevated and even substantially increased 3p levels may
be detected in the presence of modiﬁed BKPyV strains. Previous studies
have investigated BKPyV miRNA expression in plasma [28,36] and in
urinary exosomes [37] of PyVAN patients, and reported increased
miRNA expression in PyVAN patients. These ﬁndings together with ours
suggest that BKPyV miRNAs could have biomarker potential in mon-
itoring renal transplant recipients, although their role in the develop-
ment of PyVAN is still unclear and urges further studies.
Severe BKPyV disease is always associated with reactivation and
enhanced replication of persistent virus. To our knowledge, this is the
ﬁrst study preliminary investigating both the expression of BKPyV-en-
coded miRNAs and the presence of modiﬁed BKPyV strains in the
plasma of PyVAN patients. The predominance of archetype BKPyV
strains in all our patients suggests that they are suﬃcient for PyVAN
pathogenesis. Yet, our results also imply that even minor populations of
rearranged viral strains may have an impact on the balance of miRNA
expression and viral replication. In accordance with a previous study
[36], signiﬁcantly elevated BKPyV miRNA expression levels were de-
tected in biopsy-conﬁrmed PyVAN patients as compared to the controls
or presumptive PyVAN patients. Although host factors regulating
polyomavirus miRNA expression and function have not been identiﬁed,
we cannot exclude the possibility that the immunosuppressed status of
our patients might have interfered with the regulation of viral re-
plication by viral miRNAs. Despite our small study population, the
frequent detection of viral miRNAs and their increased expression levels
in PyVAN patients as well as in the presence of rearranged viral strains
point to a role of viral miRNAs in the development of PyVAN. Although
these results are preliminary and need further conﬁrmation, they
suggest that miRNA expression could provide an additional biomarker
in kidney disease.
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